Research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a hydrophilic peptide and dissolves readily in water and in aqueous buffers. The lyophilised powder is typically a white to off-white solid. Because short peptides are prone to hydrolysis and oxidation, handling benefits from limiting exposure to heat, moisture and strong light. Working solutions are commonly prepared in sterile water or saline, and repeated freeze-thaw cycles are avoided to reduce aggregation and loss of activity. These practices reflect general laboratory convention rather than published stability specifications.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid form |
| Solubility class | Freely soluble in water | Hydrophilic heptapeptide |
| Dry storage temperature | -20 degrees Celsius or lower | Sealed, desiccated, protected from light |
| Solution storage | 2 to 8 degrees Celsius short term | Avoid repeated freeze-thaw cycles |
| Common identification method | Reversed-phase HPLC with mass spectrometry | Confirms purity and molecular mass |
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Reversed-phase high-performance liquid chromatography is the standard technique for estimating peptide purity. The result is a peak-area percentage, which describes how much of the detected material elutes as the main peak in one run. Mass spectrometry confirms the molecular mass and can reveal truncated, adducted, or otherwise modified species. Amino acid analysis or tandem mass spectrometry can address sequence fidelity when identity is in doubt. None of these measurements, taken alone, establishes that a sample is fit for any specific purpose.
The Singapore government states that the death penalty is only used in the most serious of crimes, sending a strong message to potential offenders. They point out that in 1994 and 1999 the United Nations General Assembly failed to adopt United Nations resolutions calling for a moratorium on the death penalty worldwide, as a majority of countries opposed such a move. Singapore's permanent representative to the United Nations wrote a letter to the Special Rapporteur on extrajudicial, summary or arbitrary executions in 2001 which stated:
== Further reading == Arens, Sofie; Verhaegen, Jan; Verbist, Ludo (1997). "Differentiation and susceptibility ofCitrobacterisolates from patients in a university hospital". Clinical Microbiology and Infection. 3 (1): 53–57. doi:10.1111/j.1469-0691.1997.tb00251.x. ISSN 1198-743X. PMID 11864076. Janda JM, Abbott SL, Cheung WK, Hanson DF (1994). "Biochemical identification of citrobacteria in the clinical laboratory". Journal of Clinical Microbiology. 32 (8): 1850–4. doi:10.1128/JCM.32.8.1850-1854.1994. PMC 263890. PMID 7989531. Chen KJ, Chen TH, Sue YM (2013). "Citrobacter youngae and Pantoea agglomerans peritonitis in a peritoneal dialysis patient". Peritoneal Dialysis International. 33 (3): 336–7. doi:10.3747/pdi.2012.00151. PMC 3649909. PMID 23660614.
As with all catalysts, enzymes do not alter the position of the chemical equilibrium of the reaction. In the presence of an enzyme, the reaction runs in the same direction as it would without the enzyme, just more quickly. For example, carbonic anhydrase catalyzes its reaction in either direction depending on the concentration of its reactants:
Peyronie's disease diagnosis is mostly clinical. Patient history and physical examination are crucial. The most prominent features are acquired penile curvature, palpable plaques, erectile dysfunction, and pain during erections. Penile ultrasonography is the imaging method of choice for plaque location, measurement, and confirmation of calcification. Doppler ultrasound can be utilized to assess vascular function, which is useful in the evaluation of associated erectile dysfunction. Imaging also helps to differentiate Peyronie's disease from congenital penile curvature, penile fracture, or neoplastic disease. MRI can be employed in severe ones, although it is generally not required.
Sources: en.wikipedia.org
Several diseases can affect cartilage. Chondrodystrophies are a group of diseases, characterized by the disturbance of growth and subsequent ossification of cartilage. Some common diseases that affect the cartilage are listed below.
Mianserin, sold as Tolvon and other brand names, is an atypical antidepressant used primarily for treating depression in Europe and other countries. It is a tetracyclic antidepressant (TeCA) and is closely related to mirtazapine in terms of chemical structure, actions, and effects, although mianserin has greater noradrenergic activity and less 5-HT3 receptor antagonism.
Cyclosporin: see under liver effects Tacrolimus: potential pharmacokinetic interactions Other systemic antimycotic agents: with amphotericin B, itraconazole and mycophenolate, no interactions have been seen Inducers of drug clearance (e.g. carbamazepine, phenytoin, rifampin, dexamethasone): consider 70 mg intravenous as maintenance dose instead of 50 mg
increased price due to cost-intensive production; sensitivity to moisture (tablets can degrade at higher humidity); poor physical resistance (easy to break); limited ability to incorporate higher concentrations of active drug.
On 14 August 1926, Oscar Tiegs married Ethel Mary Hamilton, a telephonist, at the Presbyterian Church in the Melbourne suburb of Hawthorn. Tiegs was known to form lasting friendships, even from relatively brief associations. For example, colleagues he met only once while on a trip to Europe in 1928, had fond memories of him. He was known as Sandy Tiegs to his friends and colleagues. He was godfather to David, the son of his mentor and colleague, Professor Brailsford Robertson. Tiegs was always interested in learning and research, and was known to find administration and committee work distasteful. This would appear to be at odds with his being a Councillor, and Chair of the Library Committee, for The Royal Society of Victoria. As head of the Melbourne University's Department of Zoology, he encouraged research and empowered his staff to set their own courses of activity with a directed freedom that nurtured world class research. He tended not to be interested in the research of others unless it was closely aligned with his own, yet was proud of his staff and was keen to show visitors what his staff were doing. He lectured without notes, mainly to first year students, to whom he gave a solid background in elementary zoology and comparative morphology, in a manner which was considered a model of presentation and clarity. He gave special lectures on arthropod evolution and the vertebrate nervous system to senior students.
Sources: en.wikipedia.org
== Outlook == The long-term course of MCTD may vary. Long-term follow-up studies have shown that MCTD can progress to a moderate disease with a favorable prognosis, or patients can acquire a significant condition with vascular alterations driven by pulmonary hypertension and increased mortality. Approximately one-third of people with MCTD have a benign course and go into remission, while the other one-third have a more aggressive course with a poor response to treatment. Approximately one-third of MCTD patients improved with immunosuppressive medication but continued to require immunosuppressive therapy after several years. The prevalence of pulmonary hypertension was related to the worst prognosis and a high mortality rate, making it the most significant complication in MCTD.
=== Opioid withdrawal === Because the withdrawal effects of kratom are often reported to be less severe than those associated with traditional opioids, some people use kratom in the attempt to manage opioid use disorder. As of 2018, there have been no formal trials to study the efficacy or safety of kratom to treat opioid addiction. Stanciu et al. conducted a review of all literature and found insufficient evidence for any conclusions concerning whether kratom is harmful or whether it can serve as harm reduction for those with opioid addiction. While some literature reviews claim that kratom has less potential for dependence or overdose than traditional opioids, other reviews note that kratom withdrawal itself can still be quite severe. Data on how widely it is used worldwide are lacking, as it is not detected by typical drug screening tests. Rates of kratom use appear to be increasing among those who have been self-managing chronic pain with opioids purchased without a prescription and are cycling (but not quitting) their opioid use. In 1836, kratom was reported to have been used as an opium substitute in Malaysia. Kratom was also used as an opium substitute in Thailand in the 19th century.
== Cultural Award of the State of Hesse (2009) == In 2009, following a temporary revocation of the award, Kermani received the Hesse Cultural Award — along with Cardinal Karl Lehmann; the former president of the Church of Hesse-Nassau; Peter Steinacker; and the vice president of the Central Council of Jews, Salomon Korn. That year's ceremony was held under the theme of interreligious tolerance. The prize was offered to Kermani on March 20, 2009, after the originally intended recipient, Fuat Sezgin, had declined to accept it on the grounds that his co-recipient, Salomon Korn, supported Israel's military actions. On May 13, 2009, Kermani learned that the award intended for him had been revoked. He went on, however, to describe how this view had been shaken by what he described as the aesthetic experience: "For the first time, I thought: I — not just 'one' — I could believe in a cross." On April 24, 2009, Lehmann stated in a letter to Hesse's Minister President Roland Koch that Lehmann "cannot accept the award under these circumstances". Commentators described Lehmann's tone as "subtly ... defamatory", "smug", "mean-spirited", and "condescending"; Kermani, too, found it "defamatory". In the end, after a conversation with Kermani, Lehmann and Steinacker decided to accept the award jointly. The award was ultimately presented to the four laureates on November 26, 2009. At the ceremony, Minister President Koch apologized to Kermani. Kermani donated his prize money to Franz Meurer, the pastor of the Catholic parish of St. Theodor in Cologne-Vingst.
The Clinical Trials Facilitation Group (CTFG) of the Heads of Medicines Agency issued a Q&A document in 2017 addressing Good Laboratory Practice (GLP) requirements within the context of clinical trials for human medicines. This document aims to provide clarification and guidance on GLP principles applicable to non-clinical safety studies conducted as part of clinical trial applications. In March 2024, the Clinical Trials Coordination Group (CTCG) of the Heads of Medicines Agencies released a new recommendation paper on the principles of Good Laboratory Practices (GLP) for clinical trial applications governed by the EU Clinical Trials Regulation (Regulation (EU) No 536/2014). This paper was developed in collaboration with relevant groups from the European Medicines Agency (EMA) and the European Commission (EC) to clarify the applicable regulatory requirements and ensure transparency regarding the level of information required about GLP status in Clinical Trial Applications. This will assist researchers and sponsors in understanding what is expected and how to include the necessary information to support their applications. GLP supports the sharing of test data between countries, which helps avoid repeated testing, benefits animal welfare, and saves money for businesses and governments. Having common GLP standards also makes it easier to share information and prevents trade barriers, while helping to protect human health and the environment. The EU has established Mutual Recognition Agreements for GLP with Israel, Japan, and Switzerland.
Sources: en.wikipedia.org
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.
Reversed-phase HPLC establishes purity, while mass spectrometry confirms the expected molecular mass. Sequence confirmation may use tandem mass spectrometry or peptide mapping. A certificate of analysis typically reports these results alongside the analytical method applied.
In Russia it is a registered medicine available by prescription. In many other countries it is not approved for human use and is supplied only as a research chemical. Import and possession rules differ by jurisdiction, and buyers are responsible for checking local requirements.
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.